Ensifentrine
Published
Unassigned
New Medicines
Chronic obstructive pulmonary disease (COPD)
Information
New molecular entity
Verona Pharma
Verona Pharma
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
None
Category
RPL554 is an innovative dual phosphodiesterease (PDE) 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties
About 1.2 million people are affected by COPD in the UK. There are 115,000 new diagnoses a year. However, 60-85% of patients, mainly with mild-to-moderate disease, are thought to remain undiagnosed [9].
Chronic obstructive pulmonary disease (COPD)
Inhalation